Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Duration of Olanzapine Add-on Therapy in Major Depression
2007-000512-82Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Olanzapine add-on with Placebo add-on (2 arms). Primary endpoint: Relapse rate after response or remission. Started Aug 2007; status: completed.
02
Drugs
olanzapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2007-000512-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000512-82.